Special Issue "Autoimmune and Inflammatory Rheumatic Diseases: Potential Biomarkers, Antibodies Response and New Therapies"
Deadline for manuscript submissions: 30 April 2024 | Viewed by 6593
Interests: inflammatory rheumatic diseases; autoimmunity; T-cell response
Special Issues, Collections and Topics in MDPI journals
Autoimmune and inflammatory rheumatic diseases encompass a broad spectrum of conditions with severe disabling effects and potential organ damage. They mainly include systemic lupus erythematosus (SLE), vasculitis, rheumatoid arthritis, and spondylarthritis. Antibodies play a very important role in these diseases. In fact, several are important for pathogenesis, as exemplified by anti-native DNA antibodies associated with kidney damage in SLE, anti-neutrophil cytoplasmic antibodies (ANCAs) playing a key role in the pathogenesis of small-vessel vasculitis, and anti-citrullinated cyclic peptide (CCP) antibodies associated with an erosive course of rheumatoid arthritis. Anti-nuclear antibodies (ANAs), ANCAs, and anti-CCP antibodies also have a fundamental role in the diagnosis of these diseases. From a therapeutic point of view, monoclonal antibodies such as anti-B-cell, anti-cytokine, and anti-interleukin biologics have been used for the treatment of these conditions for the last 20 years, significantly changing the quality of life and prognosis of patients. However, important unmet needs still remain, such as the unavailability of biomarkers for diagnosis and prediction of the response to various biologics as well as the availability of more effective antibodies that may be used to target newly discovered pro-inflammatory molecules.
We invite contributions from experienced scientists and clinicians to this Special Issue of Antibodies, which hopes to further advance knowledge in this field to reduce the suffering and disability of patients with autoimmune and inflammatory rheumatic diseases.
Dr. Marino Paroli
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- antibodies and arthritis
- antibodies and connective tissue diseases
- anti-phospholipid syndrome
- anti-COVID-19 response in rheumatic diseases
- biomarkers in autoimmune/rheumatic diseases